Rate ratios were highest for critical COVID-19, and during first versus second and third pandemic waves in Sweden
Risk for Blood Clots After COVID-19 Vaccination Explored
Two studies show increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1-S
Scientists Report ‘Rogue Antibodies’ Behind Severe Clotting With COVID-19
Study authors suggest future research assess the potential benefits of screening COVID-19 patients for antiphospholipids and other autoantibodies
Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
Reporting rates 3.83 per million vaccine doses for Ad26.COV2.S versus 0.00855 per million for mRNA-based vaccines
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis
CDC Panel Advises That Other Vaccines Are Preferred Over J&J Shot
ACIP voted unanimously on Thursday afternoon on ‘updated recommendations for use’ of the single-dose vaccine
Risk Factors ID’d for Postdischarge Thrombosis in COVID-19 Patients
Risk factors for postdischarge VTE include history of VTE, peak D-dimer >3 µg/mL, predischarge CRP >10 mg/dL
Cerebral Venous Sinus Thrombosis Rate Up After Ad26.COV2.S Shot
Postvaccination CVST rate 5.1-fold higher among women compared with pre-COVID-19 pandemic rate
Therapeutic-Dose LMWH Cuts Thromboembolism, Deaths in COVID-19
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings